Novo Nordisk's Victoza shows benefit over Amylin/Lilly's Byetta
11 June 2009
Katie McQue
Please Login to read the full article.
11 June 2009
Katie McQue
katie.mcque@informa.com
Novo Nordisk's GLP-1 analogue Victoza (liraglutide) achieves greater control of blood glucose levels and has less tolerability issues than its main rival,
Amylin/
Lilly's first-in-class drug Byetta (exenatide), according to the findings of a head-to-head study, published in
The Lancet online...
Please Login to read the full article.
RELATED CONTENT
ANALYSIS
Other Informa Analysis
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
